Salix price target raised to $53 from $44 at Brean Capital

theflyonthewall.com

Brean Capital raised its price target on Salix following Q4 results. The firm cited better than expected sales for both Xifan and Relistor as well as increased guidance. Shares are Buy rated.

View Comments (0)